Schonfeld Strategic Advisors LLC Purchases Shares of 1,709,615 Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Schonfeld Strategic Advisors LLC acquired a new position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,709,615 shares of the biopharmaceutical company's stock, valued at approximately $1,744,000. Schonfeld Strategic Advisors LLC owned approximately 0.82% of Sangamo Therapeutics at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. E Fund Management Co. Ltd. bought a new stake in shares of Sangamo Therapeutics in the 4th quarter worth approximately $25,000. JPMorgan Chase & Co. boosted its holdings in Sangamo Therapeutics by 679.5% in the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 21,793 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Sangamo Therapeutics by 2,319.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 25,000 shares during the last quarter. SBI Securities Co. Ltd. bought a new position in shares of Sangamo Therapeutics during the fourth quarter valued at $28,000. Finally, Shelton Wealth Management LLC purchased a new position in shares of Sangamo Therapeutics in the 4th quarter worth about $29,000. 56.93% of the stock is currently owned by institutional investors.

Sangamo Therapeutics Stock Down 1.1 %

Shares of Sangamo Therapeutics stock opened at $0.72 on Tuesday. Sangamo Therapeutics, Inc. has a twelve month low of $0.30 and a twelve month high of $3.18. The company has a market cap of $165.02 million, a price-to-earnings ratio of -0.96 and a beta of 1.46. The company's 50 day moving average is $0.80 and its 200 day moving average is $1.38.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The firm had revenue of $7.55 million during the quarter, compared to analysts' expectations of $11.70 million. Sell-side analysts expect that Sangamo Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SGMO has been the subject of a number of analyst reports. Royal Bank of Canada restated a "sector perform" rating and set a $2.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research report on Monday, April 7th. Finally, Truist Financial lowered their price objective on Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating on the stock in a research report on Thursday, January 23rd. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Sangamo Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $5.17.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.